Related Experiment Videos
[Impaired interferon status in children with acute respiratory infection and its correction with
E A Lykova1, A A Vorob'ev, A G Bokovoĭ
1Central Clinical Hospital of the Head Office of the President of the Russian Federation, Moscow, Russia.
Insights
This study investigated interferon status in children with acute respiratory virus infections (ARVI). Bifidumbacterin forte, a probiotic, was found to positively regulate the interferon system in these patients.
Area of Science:
- Immunology
- Pediatrics
- Microbiology
Background:
- Acute respiratory virus infections (ARVI) significantly impact the immune system.
- Interferon status is a key indicator of immune response in viral infections.
- Vegetovascular dystonia serves as a comparison group for immune system evaluation.
Purpose of the Study:
- To assess interferon status in hospitalized children with complicated ARVI.
- To evaluate the regulatory effect of Bifidumbacterin forte on the interferon system.
- To determine the safety and efficacy of Bifidumbacterin forte for correcting interferon status.
Main Methods:
- Studied interferon status in 46 hospitalized children (33 with ARVI, 13 controls).
- Administered high doses of Bifidumbacterin forte (probiotic) to ARVI patients.
- Monitored changes in alpha-interferon, gamma-interferon, and serum interferon levels.
Main Results:
- Significant alterations in the interferon system were observed in children with ARVI.
- Bifidumbacterin forte enhanced alpha- and gamma-interferon induction.
- Bifidumbacterin forte decreased serum interferon production.
- The probiotic preparation was well-tolerated in high doses.
Conclusions:
- Bifidumbacterin forte demonstrates a regulatory effect on the interferon system in pediatric ARVI.
- High-dose Bifidumbacterin forte can be used to correct interferon status in children with respiratory infections.
- Probiotic intervention shows promise for immune modulation during viral infections.
Abstract:
The state of interferon status was studied in 46 hospitalized children: 33 patients with complicated forms of acute respiratory virus infection (ARVI), such as pneumonia, bronchitis, etc., and 13 patients with vegetovascular dystonia (used as a comparison group). The study revealed that in patients with acute infections of the upper and lower respiratory tract considerable changes in their interferon system were registered. Children with ARVI were treated with Bifidumbacterin forte, a probiotic preparation, in large doses. Bifidumbacterin forte was found to produce a regulatory effect on the interferon system by enhancing the induction of alpha- and gamma-interferon and decreasing the production of serum interferon. The experience of using Bifidumbacterin forte in large doses proved that the preparation was well tolerated and could be used for the correction of interferon status.